Clinical trials: PSMA PET
Prostate Cancer
High-resolution Intra-operative PSMA PET-CT in Prostate Cancer
This is a Single-center, diagnostic open-label prospective, pilot study in a total of 10 patients affected by Prostate cancer (PCa) with a risk of lymph node invasion (LNI) higher than 5% and candidates for a robot-assisted…
- Trial name
- NCT06298838
- Testing
- AURA10® Specimen PET/CT imager
- Volunteers
- 10 people
- Sponsor
- IRCCS San Raffaele
Hepatocellular Carcinoma
PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer
This clinical trial evaluates whether 68Ga-PSMA PET/MRI or PET/CT can improve upon the diagnosis and management of liver cancer.
- Trial name
- NCT04310540
- Testing
- Biopsy, Computed Tomography, Gallium Ga 68 Gozetotide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.
- Trial name
- PSMA SBRT-SIB (NCT04402151)
- Testing
- PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Weill Medical College of Cornell University
Prostatic Neoplasms
Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC
The purpose of this Radioactive Drug Research Committee (RDRC) study is to collect initial data regarding biodistribution, reproducibility, and dosimetry for the radiotracer Ga-68 PSMA-HBED-CC, an agent which may be useful for…
- Trial name
- NCT02952469
- Testing
- (68Ga)PSMA-HBED-CC
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Iowa
Hepatocellular Carcinoma (HCC)
PSMA PET for the Staging and Management of Hepatocellular Carcinoma
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC).
- Trial name
- NCT07019844
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer, Prostate Adenocarcinoma
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
- Trial name
- CONDOR (NCT03739684)
- Testing
- 18F-DCFPyL, PET/CT Imaging
- Where
- 14 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Metastatic Prostate Adenocarcinoma, PSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer
KuPSMALu-trial is an observational study for patients treated with 177LuPSMA-I\&T in Kuopio University Hospital, Finland. Study focuses on efficacy, safety and biomarker research.
- Trial name
- KuPSMALu (NCT06850545)
- Where
- Finland
- Volunteers
- 150 people
- Sponsor
- Kuopio University Hospital
Prostatic Neoplasms, Hypoxia
Effect of Hypoxia on FMISO PET to Response to Lu-177 PSMA Treatment
It is aimed to evaluate hypoxia before Lu-177 PSMA treatment in prostate cancer and to show its effect on treatment success with 18F-FMISO PET imaging, which allows in-vivo evaluation and quantification of tumor hypoxia, which is…
- Trial name
- LuMISO (NCT06433063)
- Testing
- F-MISO PET
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Cigdem Soydal
Prostate Cancer
Clinical Study on 68Ga-PSMA-33 for PET/CT Imaging of Prostate Cancer
The purpose of this study is to determine the pharmacokinetics, dosimetry, tolerance, tumor detection rate of 68Ga-PSMA-33 in patient with Prostate Cancer (PCa).
- Trial name
- NCT06054789
- Testing
- 68Ga-PSMA-33
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Prostate Cancer
Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART)
This is a retrospective monoinstitutional study which analyses the results of advanced radiotherapy (IGRT, IMRT, SBRT, and PET-guided) performed for radical, adjuvant, or salvage purposes in patients with low, intermediate, high…
- Trial name
- PROST-ART (NCT06546267)
- Testing
- Image Guided Radiotherapy, Intensity Modulated Radiotherapy, Stereotactic Body Radiotherapy
- Where
- Italy
- Volunteers
- 2,500 people
- Sponsor
- IRCCS San Raffaele
Treatment
Integrated Boost to the Dominant Intraprostatic Nodule Based on Ga-68 PSMA PET/MR Study of SBRT With Prostate Cancer
The aim of this study is to test the safety and efficacy of integrated boost to the dominant intraprostatic nodule based on Ga-68 Prostate-Specific Membrane Antigen (PSMA) PET/MR in Stereotactic Body Radiation Therapy (SBRT) in…
- Trial name
- SBRT (NCT04599699)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Changhai Hospital
Prostate Cancer
Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer
TRDC002 uses a radioactive form (64Cu) to trace the PSMA positive prostate cancer. The purpose of this study is to investigate TRDC002 as a PSMA PET tracer to localize PSMA positive lesions in adult patients with recurrent or…
- Trial name
- NCT07236112
- Testing
- Intravenous (IV) single dose
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- C Ray Therapeutics
Prostate Cancer
The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer
Obtain PSMA-PET imaging preoperatively and calculate performance for predicting extra-prostatic extension based on whole-mount pathology (gold standard).
- Trial name
- NCT04936334
- Testing
- 68Ga-PSMA-11 PET Scan
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Clinton Bahler
Prostate Cancer, Prostate Neoplasm
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
The overall goal of this research is to validate and develop a non-invasive imaging biomarker of prostate cancer detection, progression, and recurrence.
- Trial name
- NCT03232164
- Testing
- 18F-DCFPyL PET
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer Recurrent
Study of 68Ga-HBED-PSMA PET/CT and Conventional Imaging in Occult Biological Relapse Prostate Cancer
68Ga-HBED-CC-PSMA is a radiopharmaceutical allowing a new imaging modality for the detection of prostate cancer recurrences, used in recent years in clinical studies by some teams mainly in Europe (1-6 ).
- Trial name
- PSMA REBIOLOC (NCT03443609)
- Testing
- 68Ga-HBED-CC-PSMA PET / CT
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Institut Cancerologie de l'Ouest
Prostate Cancer
Model of Predicting Biochemical Recurrence After Radical Prostate Cancer Based on Pre-treatment PSMA PET / MR Image Features
The purpose of this study is to investigate the predictive value of preoperative 18F-PSMA-1007 PET/MR in the predictive effect of biological recurrence (BCR) after radical prostatectomy (RP) for localized prostate cancer (PCa).
- Trial name
- NCT06604377
- Testing
- Observe
- Where
- China
- Volunteers
- 203 people
- Sponsor
- Ruijin Hospital
Prostate Cancer
PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer
In this study, prostate cancer patients whose cancer has not spread to the lymph nodes will receive radiation therapy targeted to the prostate and nearby tissues with or without whole pelvis radiation therapy.
- Trial name
- NCT07291557
- Testing
- Prostate Only Radiation Therapy (PORT), Prostate + Whole Pelvis Radiation Therapy (P-WPRT)
- Where
- Canada
- Volunteers
- 250 people
- Sponsor
- AHS Cancer Control Alberta
Prostate Cancer
Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007
The aim of this study is to provide robust data on the head-to-head comparison of the two ligands of the prostate specific membrane antigen (PSMA) available in Switzerland for positron emission tomography (PET)-imaging, i.e.
- Trial name
- NCT05079828
- Testing
- 18F-PSMA-1007, 68Ga-PSMA-11
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Prostatic Neoplasms, Genital Neoplasms, Male
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-PSMA PET-MRI) will detect prostate cancers not seen on standard multiparametric prostate MRI…
- Conditions
- Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
- Trial name
- NCT04461509
- Testing
- 18F-PSMA
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Alessandro D'Agnolo
Prostate Cancer, High Risk
68 Ga-PSMA for High Risk Prostate Cancer
This is a prospective, single-center, open-label pilot study of 68GA-PSMA-11 given at a single time prior to PET/CT imaging in men with localized high risk prostate cancer or biochemical recurrence.
- Trial name
- NCT04614363
- Testing
- 68Ga-PSMA
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- The Methodist Hospital Research Institute